Additional Hetero Ring Is Attached Directly Or Indirectly To The Bicyclo Ring System By Nonionic Bonding Patents (Class 514/259.41)
  • Patent number: 10478436
    Abstract: Methods for treating Down syndrome and improving cognitive function of a patient with an intellectual disability are disclosed. 5-hydroxytryptamine sub-receptor six (5-HT6) receptor antagonists are provided for improving the cognition of a Down syndrome patient.
    Type: Grant
    Filed: April 8, 2015
    Date of Patent: November 19, 2019
    Assignee: THE UNIVERSITY OF UTAH RESEARCH FOUNDATION
    Inventors: Julie Ruth Korenberg, Karen Sue Wilcox, Peter Jeffrey West, Raymond Pierre Kesner
  • Patent number: 10280165
    Abstract: The invention relates to pyridopyrimidinone compounds of formula I or pharmaceutically acceptable salts thereof, wherein X, R1, R2, R3, R4, R5 and R6 are as defined herein, as well as pharmaceutical compositions comprising such compounds, and methods of treatment using such compounds.
    Type: Grant
    Filed: October 13, 2017
    Date of Patent: May 7, 2019
    Assignee: Genentech, Inc.
    Inventors: Matthew Volgraf, Yu Jiang, Elisia Villemure, Benjamin Sellers, Guosheng Wu, Aijun Lu
  • Patent number: 9963449
    Abstract: The present invention relates to a process for the preparation of pure Paliperidone Palmitate, which comprises: (a) providing a solution of Paliperidone Palmitate in an alcoholic solvent; (b) adding the alcoholic solution of Paliperidone palmitate to water or vice versa; and (c) isolating the product to obtain pure Paliperidone Palmitate.
    Type: Grant
    Filed: January 13, 2016
    Date of Patent: May 8, 2018
    Assignee: Aurobindo Pharma Ltd
    Inventors: Sandeep Jain, Srikanth Sindhanur, Anil Kumar Jain, Sivakumaran Meenakshisunderam
  • Patent number: 9751953
    Abstract: Disclosed is an antibody which binds to risperidone, which can be used to detect risperidone in a sample such as in a competitive immunoassay method. The antibody can be used in a lateral flow assay device for point-of-care detection of risperidone, including multiplex detection of aripiprazole, olanzapine, quetiapine, and risperidone in a single lateral flow assay device.
    Type: Grant
    Filed: August 20, 2013
    Date of Patent: September 5, 2017
    Assignee: JANSSEN PHARMACEUTICA NV
    Inventors: Eric Hryhorenko, Banumathi Sankaran, Thomas R. DeCory, Theresa Tubbs, Linda Colt, Maarten Vliegen, Pieter Rik Haspeslagh
  • Patent number: 9649304
    Abstract: Methods and compositions are provided for treating neuropsychiatric disorders such as schizophrenia, depression, attention deficit disorder, mild cognitive impairment, dementia, and bipolar disorder. The methods entail administering to a patient diagnosed as having a neuropsychiatric disorder (e.g., schizophrenia, depression, attention deficit disorder, mild cognitive impairment, dementia bipolar disorder, etc.) or as at risk for a neuropsychiatric disorder a benzoic acid, benzoic acid salt, and/or benzoic acid derivative, and/or a sorbic acid, sorbic acid salt, and/or sorbic acid derivative, in combination with a neuropharmacological agent (e.g., an antipsychotic, an antidepressant, medications for attention deficit and hyperactivity disorder, cognitive impairment, or dementia, etc.) where the benzoic acid, benzoic acid salt, or benzoic acid derivative, and/or a sorbic acid, sorbic acid salt, and/or sorbic acid derivative, is in an amount sufficient to increase the efficacy of the neuropharmacological agent.
    Type: Grant
    Filed: January 19, 2010
    Date of Patent: May 16, 2017
    Assignee: Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center
    Inventor: Guochuan Emil Tsai
  • Patent number: 9320707
    Abstract: The present invention is concerned with a pharmaceutical composition suitable as a depot formulation for administration via intramuscular or subcutaneous injection, comprising: (1) as an active ingredient a therapeutically effective amount of a 9-hydroxyrisperidone fatty acid ester or a salt, or a stereoisomer or a stereoisomeric mixture thereof in submicron form and (2) a pharmaceutically acceptable carrier; wherein the pharmaceutically acceptable carrier is water and the active ingredient is suspended therein: and with a process of preparing such a composition. The invention further concerns such a pharmaceutical composition for use as a medicament in the treatment of psychosis, schizophrenia, schizoaffective disorders, non-schizophrenic psychoses, behavioral disturbances associated with neurodegenerative disorders, e.g. in dementia, behavioral disturbances in mental retardation and autism, Tourette's syndrome, bipolar mania, depression, anxiety.
    Type: Grant
    Filed: June 29, 2012
    Date of Patent: April 26, 2016
    Assignee: Janssen Pharmaceutica, N.V.
    Inventors: Marc Karel Jozef François, Willy Maria Albert Carlo Dries, Esther Dina Guido Basstanie
  • Patent number: 9072743
    Abstract: The present specification discloses compositions comprising at least one therapeutic compound capable of modulating androgen production and methods and uses for treating a disorder associated with androgen production using such compositions and/or compounds.
    Type: Grant
    Filed: September 26, 2013
    Date of Patent: July 7, 2015
    Assignee: Tangent Reprofilling Limited
    Inventors: Suzanne Dilly, Gregory Stoloff, Paul Taylor
  • Publication number: 20150147398
    Abstract: An injectable intramuscular depot composition suitable for forming an in situ solid implant in a body, comprising a drug which is paliperidone and/or its pharmaceutical acceptable salts in any combination thereof, a biocompatible copolymer based on lactic and glycolic acid having a monomer ratio of lactic to glycolic acid of about 50:50 and DMSO as solvent, wherein the composition releases the drug with an immediate onset of action and continuously for at least 8 weeks and wherein the composition has a pharmacokinetic profile in vivo suitable for the formulation to be administered each 8 weeks or even longer periods.
    Type: Application
    Filed: November 26, 2014
    Publication date: May 28, 2015
    Applicant: Laboratorios Farmacéuticos Rovi, S.A.
    Inventors: Ibon GUTIERRO ADURIZ, Guillermo FRANCO RODRÍGUEZ
  • Patent number: 9040695
    Abstract: The present invention relates to a novel acid addition salt of risperidone, wherein acid counterion is selected from the group consisting of pamoic acid, caproic acid, cypionic acid, decanoic acid, camphor sulfonic acid, enanthic acid, palmitic acid, fusidic acid, gluceptic acid, gluconic acid, lactobionic acid, lauric acid, levulinic acid and valeric acid, a process for the preparation and pharmaceutical composition comprising the same. Further, the invention relates to the use of said pharmaceutical composition comprising the acid addition salt of risperidone in the treatment of patient suffering from psychotic disorders.
    Type: Grant
    Filed: April 25, 2012
    Date of Patent: May 26, 2015
    Assignee: TORRENT PHARMACEUTICALS LIMITED
    Inventors: Sunil Sadanand Nadkarni, Arunkumar Gupta, Manish Parikh, Jaya Abraham, Vivek Mishra
  • Publication number: 20150141380
    Abstract: A method of treating a subject at risk of or suspected of having Fragile X syndrome or autism spectrum disorder associated with abnormalities of ERK includes administering to the subject a therapeutically effective amount of at least one ERK inhibiting compound that prevents abnormalities in neuronal connectivity, a prodrug thereof that is metabolisable to form the compound, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: August 5, 2011
    Publication date: May 21, 2015
    Applicant: CASE WESTERN RESERVE UNIVERSITY
    Inventors: Mark A. Smith, Michael Snape
  • Publication number: 20150126496
    Abstract: The invention relates to methods for diagnosis and treatment of autism spectrum disorders, particularly for autism spectrum disorders characterized by increased head size (circumference) and deficits in social behavior.
    Type: Application
    Filed: October 10, 2014
    Publication date: May 7, 2015
    Applicant: Massachusetts Institute of Technology
    Inventors: Damon Theron Page, Mriganka Sur
  • Publication number: 20150119383
    Abstract: Embodiments disclosed herein generally relate to acamprosate formulations, methods of use of the formulations, to methods of using the formulations in combination with at least one other medication, and to combination products and compositions comprising the formulations and at least one other medication, such as neuroleptic (antipsychotic) and/or antidepressant drugs.
    Type: Application
    Filed: June 5, 2014
    Publication date: April 30, 2015
    Inventors: Barry S. Fogel, William D. Kerns, Kei-Lai Fong, San-Laung Chow, Edward Lin, David Wong
  • Patent number: 9017735
    Abstract: Disclosed herein are compositions and methods for treating a psychiatric disorder or symptoms thereof in a patient. The compositions comprise a compound that modulates KCNQ (Kv7) potassium channel activity and the methods include administering an effective amount of the compound that modulates KCNQ (Kv7) potassium channel activity.
    Type: Grant
    Filed: June 3, 2010
    Date of Patent: April 28, 2015
    Assignee: Marquette University
    Inventor: Mohammadhossein Behnam Ghasemzadeh
  • Publication number: 20150111834
    Abstract: The disclosure provides a recipe for in-situ gel, formed by dissolving at least one polymer and at least one gel prevention agent in a polar solvent to form a solution and placing the solution in a condition for in-situ forming gels. The disclosure also provides an implant and a drug delivery system formed by the recipe.
    Type: Application
    Filed: September 17, 2014
    Publication date: April 23, 2015
    Applicant: INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE
    Inventors: Felice CHENG, Maggie J.M. LU, Yi-Ju KO, Min-Ying LIN, Shuen-Hsiang CHOU
  • Patent number: 9011912
    Abstract: Oral dosage forms for poorly soluble amine drugs are provided. Such dosage forms include an ionizable compound such as an organic acid, an amphiphilic polymer and a release rate-controlling membrane. Such dosage forms allow for the consistent release of the active agent in both gastric pH conditions and in the intestine. Methods of making such dosage forms are also provided.
    Type: Grant
    Filed: October 7, 2010
    Date of Patent: April 21, 2015
    Assignee: Abon Pharmaceuticals, LLC
    Inventors: Yanming Zu, Sudhir Gorukanti, Salah Uddin Ahmed
  • Patent number: 9006431
    Abstract: There is provided a hemihydrate form of the sodium salt of pemirolast.
    Type: Grant
    Filed: May 12, 2014
    Date of Patent: April 14, 2015
    Assignee: RSPR Pharma AB
    Inventors: Anett Perlberg, Martin Viertelhaus, Ulrika Rosenström, Karol Horvath
  • Publication number: 20150099015
    Abstract: Methods and compositions are provided for treating neuropsychiatric disorders such as schizophrenia, depression, attention deficit disorder, mild cognitive impairment, dementia, and bipolar disorder. The methods entail administering to a patient diagnosed as having a neuropsychiatric disorder (e.g., schizophrenia, depression, attention deficit disorder, mild cognitive impairment, dementia bipolar disorder, etc.) or as at risk for a neuropsychiatric disorder a benzoic acid, benzoic acid salt, and/or benzoic acid derivative, and/or a sorbic acid, sorbic acid salt, and/or sorbic acid derivative, in combination with a neuropharmacological agent (e.g., an antipsychotic, an antidepressant, medications for attention deficit and hyperactivity disorder, cognitive impairment, or dementia, etc.) where the benzoic acid, benzoic acid salt, or benzoic acid derivative, and/or a sorbic acid, sorbic acid salt, and/or sorbic acid derivative, is in an amount sufficient to increase the efficacy of the neuropharmacological agent.
    Type: Application
    Filed: November 24, 2014
    Publication date: April 9, 2015
    Inventor: Guochuan Emil TSAI
  • Publication number: 20150099767
    Abstract: The present invention relates to a risperidone sustained release delivery system for treatment of medical conditions relating delusional psychosis, schizophrenia, bipolar disorder, psychotic depression, obsessive-compulsion disorder, Tourette syndrome, and autistic spectrum disorders. The sustained release delivery system includes a flowable composition containing risperidone, a metabolite, or a prodrug thereof and an implant containing risperidone, a metabolite, or a prodrug thereof. The flowable composition may be injected into tissue whereupon it coagulates to become the solid or gel, monolithic implant. The flowable composition includes a biodegradable, thermoplastic polymer, an organic liquid, and risperidone, a metabolite, or a prodrug thereof.
    Type: Application
    Filed: September 18, 2014
    Publication date: April 9, 2015
    Inventor: Eric Dadey
  • Publication number: 20150080372
    Abstract: Compounds and salts thereof, formulations thereof, conjugates thereof, derivatives thereof, forms thereof and uses thereof are described. In certain aspects and embodiments, the described compounds or salts thereof, formulations thereof, conjugates thereof, derivatives thereof, forms thereof are active on each of B-Raf, B-Raf V600E and c-Raf-1 protein kinase. In certain aspects and embodiments, the described compounds are active in inhibiting proliferation of a Ras mutant cell line.
    Type: Application
    Filed: October 14, 2014
    Publication date: March 19, 2015
    Inventors: Prabha N. Ibrahim, Guoxian Wu, Jack Lin, Wayne Spevak, Hanna Cho, Todd Ewing, Chao Zhang
  • Patent number: 8980900
    Abstract: The present invention provides the use of certain compounds to treat peripheral or central pain syndrome and other disorders associated with the T-type calcium ion channels.
    Type: Grant
    Filed: September 9, 2014
    Date of Patent: March 17, 2015
    Assignee: VM Therapeutics, LLC.
    Inventor: Jay Jie-Qiang Wu
  • Publication number: 20150064118
    Abstract: The present invention relates to pre-formulations comprising low viscosity, non-liquid crystalline, mixtures of: a) at least one neutral diacyl lipid and/or at least one tocopherol; b) at least one phospholipid; c) at least one biocompatible, oxygen containing, low viscosity organic solvent; wherein at least one bioactive agent is dissolved or dispersed in the low viscosity mixture and wherein the pre-formulation forms, or is capable of forming, at least one liquid crystalline phase structure upon contact with an aqueous fluid. The preformulations are suitable for generating parenteral, non-parenteral and topical depot compositions for sustained release of active agents. The invention additionally relates to a method of delivery of an active agent comprising administration of a preformulation of the invention, a method of treatment comprising administration of a preformulation of the invention and the use of a preformulation of the invention in a method for the manufacture of a medicament.
    Type: Application
    Filed: September 15, 2014
    Publication date: March 5, 2015
    Inventors: Krister THURESSON, Fredrik TIBERG, Markus JOHANSSON, Ian HARWIGSSON, Fredrik JOABSSON, Markus JOHNSSON
  • Patent number: 8940749
    Abstract: An improved process for the synthesis of 3-[2-[4-((6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-6,7,8,9-tetrahydro-9-hydroxy-2-methyl-4H-pyrido[1,2-a]-pyrimidin-4-one (Paliperidone) and Paliperidone Palmitate through a novel intermediate (2-Chloroethyl)-6,7,8,9-tetrahydro-2-methyl-9-hydroxy-4H-pyrido [1,2-a]pyrimidine-4-one Palmitate ester.
    Type: Grant
    Filed: May 30, 2012
    Date of Patent: January 27, 2015
    Inventors: Ramamohan Rao Davuluri, Ravi Ponnaiah, Praveen Kumar Neela, Guruswamy Batthini, Telagareddy Venkata Narasimharao, Kosireddy Ravanababu, Kallepally Sudheer
  • Publication number: 20150005323
    Abstract: The present invention relates to a risperidone sustained release delivery system for treatment of medical conditions relating delusional psychosis, schizophrenia, bipolar disorder, psychotic depression, obsessive-compulsion disorder, Tourette syndrome, and autistic spectrum disorders. The sustained release delivery system includes a flowable composition containing risperidone, a metabolite, or a prodrug thereof and an implant containing risperidone, a metabolite, or a prodrug thereof. The flowable composition may be injected into tissue whereupon it coagulates to become the solid or gel, monolithic implant. The flowable composition includes a biodegradable, thermoplastic polymer, an organic liquid, and risperidone, a metabolite, or a prodrug thereof.
    Type: Application
    Filed: September 18, 2014
    Publication date: January 1, 2015
    Inventor: Eric Dadey
  • Patent number: 8920835
    Abstract: A paliperidone double-layered osmotic pump controlled release tablet and the preparation method thereof are disclosed. The double-layered osmotic pump controlled release tablet comprises a rigid membrane, a push layer, a drug layer, an isolation layer and an aesthetic coating, wherein the rigid membrane contains a semi-permeable polymer, a porogen and/or a plasticizer and has one or more drug release orifices on one end, the push layer comprises an expanding material, an osmotic agent, a binder, a colorant and a lubricant, the drug layer contains a pharmaceutically active ingredient, a hydrophilic polymer, an osmotic agent, a colorant, a lubricant and an antistatic agent, the isolation layer is located between the inner surface of the rigid membrane and the push layer, and contains a hydrophilic polymer. The paliperidone double-layered osmotic pump controlled release tablet shows an increasing drug release rate at early stage and keeps a constant drug release rate at later stage.
    Type: Grant
    Filed: November 22, 2010
    Date of Patent: December 30, 2014
    Assignees: Shanghai Institute of Materia Medica, Chinese Academy of Sciences, QILU Pharamceutical Co., Ltd.
    Inventors: Yong Gan, Chunliu Zhu, Qingmin Yang, Jingyi Wang, Xiaoqing Zheng, Li Gan, Xinxin Zhang
  • Publication number: 20140378476
    Abstract: The present invention provides the use of certain compounds to treat peripheral or central pain syndrome and other disorders associated with the T-type calcium ion channels.
    Type: Application
    Filed: September 9, 2014
    Publication date: December 25, 2014
    Inventor: Jay Jie-Qiang Wu
  • Publication number: 20140378475
    Abstract: Disclosed are compounds of Formula (I) wherein: the two dotted lines represent either two single or two double bonds; Q is: R1 is F, Cl, —CN, or —CH3; R2 is Cl or —CH3; R3 is —C(CH3)2OH or —CH2CH2OH; Ra is H or —CH3; each Rb is independently F, Cl, —CH3, and/or —OCH3; and n is zero, 1, or 2. Also disclosed are methods of using such compounds as inhibitors of Bruton's tyrosine kinase (Btk), and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.
    Type: Application
    Filed: June 25, 2014
    Publication date: December 25, 2014
    Inventors: Douglas G. Batt, Myra Beaudoin Bertrand, George Delucca, Michael A. Galella, Soo Sung Ko, Charles M. Langevine, Qingjie Liu, Qing Shi, Anurag S. Srivastava, Joseph A. Tino, Scott Hunter Watterson
  • Publication number: 20140356292
    Abstract: A method of evaluating memory/learning functions with the use of a model with glutamic acid N-methyl-D-aspartate (NMDA) type receptor hypofunction as an animal model for schizophrenia and with the use of reference memory task, wherein there has been found concrete means for detecting any differences in activity between typical anti-psychosis drugs and atypical anti-psychosis drugs is found. An in vivo animal model for screening of a therapeutic agent for improving cognitive dysfunction by schizophrenia is provided.
    Type: Application
    Filed: August 14, 2014
    Publication date: December 4, 2014
    Applicant: Sumitomo Dainippon Pharma Co., Ltd.
    Inventor: Takeo ISHIYAMA
  • Publication number: 20140350000
    Abstract: This document provides methods and materials related to genetic markers for predicting response to a treatment for schizophrenia (SZ). For example, methods for using such genetic markers to select optimal treatments are provided.
    Type: Application
    Filed: August 13, 2014
    Publication date: November 27, 2014
    Inventors: Mark David Brennan, Timothy Lynn Ramsey
  • Publication number: 20140349999
    Abstract: The present invention relates to the discovery of a novel opioid modulator effective in reducing pharmacologically induced weight gain associated with atypical antipsychotic use. The present invention provides methods of reducing antipsychotic induced weight gain, methods for suppressing food intake and reducing ghrelin levels induced by atypical antipsychotic medications in a patient.
    Type: Application
    Filed: June 5, 2014
    Publication date: November 27, 2014
    Inventors: Daniel Deaver, Mark Todtenkopf
  • Publication number: 20140343080
    Abstract: The present invention provides implants comprising a therapeutic drug and a polymer containing polylactic acid (PLA) and optionally polyglycolic acid (PGA). The present invention also provides methods of maintaining a therapeutic level of a drug in a subject, releasing a therapeutic drug at a substantially linear rate, and treating schizophrenia and other diseases and disorders, utilizing implants of the present invention.
    Type: Application
    Filed: May 23, 2014
    Publication date: November 20, 2014
    Applicant: The Trustees of the University of Pennsylvania
    Inventors: Steven SIEGEL, Karen Winey
  • Publication number: 20140329839
    Abstract: There is provided a hemihydrate form of the sodium salt of pemirolast.
    Type: Application
    Filed: May 12, 2014
    Publication date: November 6, 2014
    Applicant: CARDOZ AB
    Inventors: Anett Perlberg, Martin Viertelhaus, Ulrika Rosenström, Karol Horvath
  • Publication number: 20140315892
    Abstract: The present invention relates to (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane and pharmaceutically acceptable salts thereof, compositions comprising (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane or a pharmaceutically acceptable salt thereof, and methods for treating or preventing an alcohol-related or addictive disorder. The (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.
    Type: Application
    Filed: January 31, 2014
    Publication date: October 23, 2014
    Inventors: Anthony Alexander McKinney, Franklin Porter Bymaster
  • Patent number: 8865727
    Abstract: The present invention provides the use of certain compounds to treat peripheral or central pain syndrome and other disorders associated with the T-type calcium ion channels.
    Type: Grant
    Filed: August 27, 2010
    Date of Patent: October 21, 2014
    Assignee: VM Therapeutics LLC
    Inventor: Jay Jie-Qiang Wu
  • Publication number: 20140309181
    Abstract: Small compounds that modulate the expression of and/or function of sodium channel, voltage-gated, alpha subunit (SCNxA) are presented. Pharmaceutical compositions containing such small molecules and their use in treating diseases and disorders associated with the expression of SCNxA are also presented.
    Type: Application
    Filed: August 28, 2012
    Publication date: October 16, 2014
    Applicant: CuRNA, Inc.
    Inventors: Joseph Collard, Olga Khorkova Sherman, Jane H. Hsiao
  • Publication number: 20140308352
    Abstract: Compositions may include a pharmaceutical active agent, a high viscosity liquid carrier material (HVLCM), a lactic acid-based polymer, and an organic solvent. Related compositions and methods are also disclosed.
    Type: Application
    Filed: March 11, 2014
    Publication date: October 16, 2014
    Applicants: ZOGENIX INC., DURECT CORPORATION
    Inventors: Jeremy C. WRIGHT, Wilma TAMRAZ, John J. LEONARD, John W. GIBSON, Keith E. BRANHAM, Stefania SJOBECK, Brooks BOYD, Christopher M. RUBINO
  • Patent number: 8859563
    Abstract: The present invention provides a compound of Formula I or a pharmaceutically acceptable derivative, salt or prodrug thereof. Further provided is a method of treatment or prophylaxis of a viral infection in a subject comprising administering to said subject an effective amount of a compound of Formula I or a pharmaceutically acceptable derivative, salt or prodrug thereof. A pharmaceutical composition or medicament comprising a compound of Formula I is also provided.
    Type: Grant
    Filed: February 27, 2012
    Date of Patent: October 14, 2014
    Assignee: Avexa Limited
    Inventors: Eric Dale Jones, Jonathan Alan Victor Coates, David Ian Rhodes, John Joseph Deadman, Nicholas Andrew Van de Graff, Lisa Jane Winfield, Neeranat Thienthong, William Issa, Neil Choi, Katherine Macfarlane
  • Publication number: 20140303189
    Abstract: The invention provides a patch containing a support and, formed thereon, an adhesive layer retaining a drug. The adhesive layer contains a thermoplastic elastomer, a liquid component in an amount exceeding 300 parts by weight relative to 100 parts by weight of the elastomer, and risperidone or a salt thereof, and optionally a tackifier of not more than 10 wt %.
    Type: Application
    Filed: August 17, 2012
    Publication date: October 9, 2014
    Applicant: KM TRANSDERM LTD.
    Inventors: Masaoki Goto, Atsuyo Hamada, Mitsuji Akazawa, Keiko Yamasaki, Shoji Miyaji
  • Publication number: 20140296140
    Abstract: An equipment assembly for preparing, harvesting and collecting particles is disclosed. The assembly comprises a tandem filter system with one or more high pressure filters, one or more low pressure filters and one or more collection vessel. Particles can be prepared, harvested and collected continuously, semi-continuously or in a batch-type operation. A tandem filter system and its method of use are also disclosed. Particles made with the assembly and according the instant methods are also disclosed. The assembly provides improved particle harvesting and collection over other systems and permits continuous particle formation, in particular by dispersion of a solute-containing process fluid within a supercritical anti-solvent.
    Type: Application
    Filed: June 17, 2014
    Publication date: October 2, 2014
    Applicant: CRITITECH, INC.
    Inventors: Greg S. JOHNSON, Bala SUBRAMANIAM, Fenghui Niu
  • Publication number: 20140296257
    Abstract: The present invention relates to water-soluble carrier-linked prodrugs of formula (I), wherein B, A and Hyp form the carrier, B is a branching core, each A is independently a poly(ethylene glycol)-based polymeric chain, each Hyp is independently a branched moiety, each SP is independently a spacer moiety, each L is independently a reversible prodrug linker moiety, each D is independently a biologically active moiety, each x is independently 0 or 1, each m is independently an integer of from 2 to 64, n is an integer from 3 to 32; or the pharmaceutically acceptable salt thereof. It further relates to pharmaceutical compositions comprising said water-soluble carrier-linked prodrugs, their use as medicament or diagnostic, and methods of treatment.
    Type: Application
    Filed: August 10, 2012
    Publication date: October 2, 2014
    Applicant: Ascendis Pharma A/S
    Inventors: Ulrich Hersel, Guillaume Maitro, Harald Rau, Dirk Vetter
  • Publication number: 20140288054
    Abstract: This invention relates to genetic markers of mental illness, e.g., schizophrenia (SZ), and methods of use thereof.
    Type: Application
    Filed: October 29, 2013
    Publication date: September 25, 2014
    Applicant: SureGene, LLC
    Inventors: Mark David Brennan, Timothy Lynn Ramsey
  • Publication number: 20140255517
    Abstract: In certain embodiments, the disclosure relates to methods of treating or preventing posttraumatic stress disorder comprising administering a pharmaceutical composition comprising effective amount of an angiotensin-converting enzyme inhibitor to a subject in need thereof. In certain embodiments, the angiotensin-converting enzyme inhibitor is administered in combination with an angiotensin receptor blocker.
    Type: Application
    Filed: March 5, 2014
    Publication date: September 11, 2014
    Applicant: EMORY UNIVERSITY
    Inventors: Kerry J. Ressler, Paul J. Marvar
  • Publication number: 20140248378
    Abstract: The present invention provides compounds of formula (1) and pharmaceutically acceptable salts thereof, wherein R1, R2, Y and Z are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
    Type: Application
    Filed: July 5, 2012
    Publication date: September 4, 2014
    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Xiao-Ling Fan Cockcroft, William Farnaby, Natasha Kinsella, Kevin Merchant, David Miller
  • Publication number: 20140242063
    Abstract: The present invention provides for a pharmaceutical composition that includes tetrabenazine and a release-retarding agent; and a method of treating a hyperkinetic movement disorder (e.g., Huntington's disease, chorea associated with Huntington's disease, hemiballismus, senile chorea, tic disorders, tardive dyskinesia, myoclonus, dystonia and/or Tourette's syndrome). The method includes administering an effective amount of the pharmaceutical composition, for a period of time effective to treat the hyperkinetic movement disorder.
    Type: Application
    Filed: October 10, 2013
    Publication date: August 28, 2014
    Applicant: VALEANT LABORATORIES INTERNATIONAL BERMUDA
    Inventors: Andrew John DUFFIELD, Graham JACKSON, Steven E. FRISBEE
  • Publication number: 20140242088
    Abstract: A pharmaceutical combination comprising an Hsp90 inhibitor and an mTOR inhibitor, and methods of using the combination to treat or prevent proliferative disorders.
    Type: Application
    Filed: April 30, 2014
    Publication date: August 28, 2014
    Applicant: Novartis AG
    Inventors: Carlos Garcia-Echeverria, Michael Rugaard Jensen
  • Publication number: 20140234443
    Abstract: Novel 5-HT3 receptor modulators are disclosed. These compounds are used in the treatment of various disorders, including chemotherapy-induced nausea and vomiting, post-operative nausea and vomiting, and irritable bowel syndrome. Methods of making these compounds are also described in the present invention.
    Type: Application
    Filed: March 10, 2014
    Publication date: August 21, 2014
    Applicant: Albany Molecular Research, Inc.
    Inventors: Peter R. GUZZO, David D. MANNING, William EARLEY
  • Patent number: 8808746
    Abstract: Provided, among other things, are compositions and methods for making sustained-release microspheres, as well as a microsphere delivery system for the sustained release of an active agent. The microsphere delivery system comprises a homogeneous mixture of biodegradable polymer, active agent, and a so-called release-modifying agent (including a pH-stabilizing agent), and provides protected and sustained release of active agents from the microsphere delivery system. According to the invention, the microspheres preferably are produced by an oil-in-water emulsion method that involves the production of a homogeneous oil phase prepared by mixing active agent and a release-modifying agent, such as arginine, with biodegradable polymer, each dissolved in organic solvent.
    Type: Grant
    Filed: April 29, 2005
    Date of Patent: August 19, 2014
    Assignee: Fresenius Kabi USA, LLC
    Inventors: Byung Ho Woo, Sumeet H. Dagar, Kang Yong Yang
  • Publication number: 20140206536
    Abstract: Disclosed are compounds of Formula 1, N-oxides, and salts thereof, wherein X is O or S; Y is O or S; A is O, S, NR3e or C(R3c)?C(R3d); Z is a direct bond, O, S(O)n, NR6, C(R7)2O, OC(R7)2, C(?X1), C(?X1)E, EC(?X1), C(?NOR8) or C(?NN(R6)2); a is 1, 2 or 3; and R1, R2, R3a-R3e, R4, R5, R6, R7, R8, X1 and E are as defined in the disclosure. Also disclosed are compositions containing the compounds of Formula 1 and methods for controlling an invertebrate pest comprising contacting the invertebrate pest or its environment with a biologically effective amount of a compound or a composition of the invention.
    Type: Application
    Filed: March 19, 2014
    Publication date: July 24, 2014
    Applicant: E I DU PONT DE NEMOURS AND COMPANY
    Inventors: WENMING ZHANG, CALEB WILLIAM HOLYOKE, JR., KENNETH ANDREW HUGHES, GEORGE PHILIP LAHM, THOMAS FRANCIS PAHUTSKI, JR., MY-HANH THI TONG, MING XU
  • Publication number: 20140206667
    Abstract: The invention relates to methods and compositions for treating schizophrenia or bipolar disorder (in particular, mania) by using a combination of a synaptic vesicle protein 2A (SV2A) inhibitor and an antipsychotic or their pharmaceutically acceptable salts, hydrates, solvates, polymorphs thereof. In some embodiments, the methods and the compositions are for treating one or more positive and/or negative symptoms, as well as cognitive impairment, associated with schizophrenia or bipolar disorder (in particular, mania).
    Type: Application
    Filed: November 14, 2013
    Publication date: July 24, 2014
    Inventor: Michela Gallagher
  • Publication number: 20140200228
    Abstract: The present invention provides a process for the preparation of paliperidone or a pharmaceutically acceptable salt thereof, wherein the process comprises condensing a compound of formula (II) with a compound of formula (III) or a salt thereof, in a suitable solvent and a base, in the presence of a catalyst and an inhibiting agent, wherein the inhibiting agent is added to the reaction system before the compound of formula (II) and compound of formula (III) have reacted or as the reaction of the compound of formula (II) and compound of formula (III) is initiated, and optionally converting the paliperidone to a salt thereof, wherein X is a suitable leaving group. The present invention also provides substantially pure paliperidone or a salt thereof, paliperidone or a salt thereof as prepared by the process and uses of the paliperidone or salt thereof.
    Type: Application
    Filed: May 30, 2012
    Publication date: July 17, 2014
    Applicant: CIPLA LIMITED
    Inventors: Ravikumar Puppala, Srinivas Laxminarayan Pathi, Rajendra Narayanrao Kankan
  • Publication number: 20140193347
    Abstract: The present invention relates to pre-formulations comprising low viscosity, non-liquid crystalline, mixtures of: a) at least one neutral diacyl lipid and/or at least one tocopherol; b) at least one phospholipid; c) at least one biocompatible, oxygen containing, low viscosity organic solvent; wherein at least one bioactive agent is dissolved or dispersed in the low viscosity mixture and wherein the pre-formulation forms, or is capable of forming, at least one liquid crystalline phase structure upon contact with an aqueous fluid. The preformulations are suitable for generating parenteral, non-parenteral and topical depot compositions for sustained release of active agents. The invention additionally relates to a method of delivery of an active agent comprising administration of a preformulation of the invention, a method of treatment comprising administration of a preformulation of the invention and the use of a preformulation of the invention in a method for the manufacture of a medicament.
    Type: Application
    Filed: September 4, 2013
    Publication date: July 10, 2014
    Applicant: CAMURUS AB
    Inventors: Krister THURESSON, Fredrik TIBERG, Markus JOHANSSON, Ian HARWIGSSON, Fredrik JOABSSON, Markus JOHNSSON